Neurogenic is setting a new pace for precision psychiatry.

Changing the course of schizophrenia starts with early detection.

Neurogenic is a precision diagnostics company developing vital, objective laboratory support when a precise diagnosis is crucial. Powered by a blood-based biomarker assay, our platform serves as an adjunctive aid designed to integrate seamlessly alongside standard clinical assessments. By combining decades of advanced research with clinical utility, this objective biological data empowers medical judgment, resolves diagnostic ambiguity, and transforms how childhood and adolescent schizophrenia-spectrum illnesses are evaluated to fast-track young patients to targeted care.

An Adjunctive Diagnostic Aid

Providing clinicians with the biological specificity needed to differentiate underlying schizophrenia-spectrum pathology from alternative, overlapping psychiatric conditions in pediatric and adolescent patients.

A Prognostic Tool for TRS Stratification

Utilizing hyper-elevated baseline biological markers to early-identify patients likely to fail standard first-line oral antipsychotics, bypassing years of agonizing therapeutic trial-and-error.

Schizophrenia-Spectrum Pathology: The Critical Window for intervention.

The Timeline of Onset

Schizophrenia affects approximately 1% of the population worldwide, making it a major driver of global clinical disability. While formal diagnosis typically peaks in early adulthood around age 20, the actual pathological onset begins much earlier. For a vast majority of young patients, subtle cognitive, social, and behavioral warning signs emerge years before a catastrophic psychotic break, opening a critical but frequently missed window for early biological detection.

The Diagnostic Maze

Initial signs of schizophrenia-spectrum pathology heavily overlap with a broad range of pediatric and juvenile conditions, forcing clinicians into a profound dilemma. Without objective data, the fear of permanently labeling a child or teenager leads to defensive diagnostic reluctance, leaving vulnerable patients to spend their most critical, formative years in clinical limbo.

The Cost of Active Uncertainty

When clinical intuition is forced to rely on months of behavioral observation alone, the clock works against the patient. Young minds are forced into a cycle of therapeutic trial-and-error, moving from one ineffective treatment to the next while the underlying pathology quietly progresses. For the significant portion of patients with an underlying treatment-resistant phenotype, this delay doesn’t just stall recovery—it actively entrenches the illness.

Key Opinion Leader Spotlight

“Psychosis emerges in youth, a period in which a life’s trajectory is being set. The longer an individual remains with symptoms, the more self-reinforced these may become. Offering effective treatment as early as possible maximizes the chance of shifting a dysfunctional system into a more adaptive state while patterns are still malleable… we can prevent the entrenchment of disability and offer individuals the best possible chance of recovery when everything is still to play for.”

— McCutcheon et al., World Psychiatry (2026)

The Intervention

By replacing behavioral ambiguity with an objective, blood-based molecular signature at initial presentation, we empower physicians to do what was previously impossible:

Differentiate with Confidence:

Instantly cut through complex symptom overlap to help distinguish true schizophrenia-spectrum pathology from alternative childhood developmental regressions or transient adolescent emotional crises.

Identify Resistance on Day One:

Unmask treatment-resistant phenotypes early in the care pathway, allowing clinicians to bypass years of toxic, ineffective medication cycles and fast-track young patients directly to definitive, targeted therapies.

Interrupt the Feedback Loops:

Deliver the biological clarity required to intervene while a child’s or teenager’s brain is still highly adaptive—protecting vital developmental, educational, and personal milestones before chronic disability can take hold.

The Science & Translation Pipeline.

Our proprietary nsPAA technology has moved past pure theoretical discovery. By anchoring our patented biological findings in standard laboratory frameworks, we are actively building a predictable, industrialized pathway to the clinic.

1. Clinically Validated
Origins

Proven Biological Foundations

The core biological mechanism of our nsPAA ELISA platform has been robustly validated across rigorous clinical cohorts. By evaluating real-world pediatric and adolescent patient data, we successfully demonstrated the assay’s high biological specificity to differentiate underlying schizophrenia-spectrum pathology early in the disease course.

2. Industrialized
Scale

Commercial Assay Engineering

To ensure seamless global clinical adoption, we are actively transitioning our proprietary laboratory Standard Operating Procedures (SOPs) into a robust, scalable commercial kit. Partnering with DCN Dx, a world-class leader in diagnostic assay development in the United States, we are optimizing our dimeric peptide ELISA for maximum reproducibility, stability, and high-throughput laboratory performance.

3. Regulatory Validation & FDA Strategy

Prospective Multi-Center Validation

Neurogenic is actively preparing the regulatory infrastructure to initiate our prospective, multi-center observational clinical validation study in the United States. This targeted trial is meticulously designed to provide the definitive clinical performance data required to support our upcoming FDA regulatory submission pathway, validating our industrialized nsPAA kit as a trusted, prescription-use adjunctive aid for pediatric and adolescent populations (ages 6–12 and 13–19).

Watch Our Story.

The Science of Certainty: The nsPAA ELISA Platform.

Our technology is the culmination of a deliberate scientific journey. Rather than relying on simple clinical observation, our team tracked a raw biological clue, significantly elevated autoantibody activity in patients, and systematically isolated the specific antibodies responsible. By proving these antibodies directly interact with central nervous system pathways, we successfully mapped an unmapped autoimmune signature, moving from broad biological activity to pinpointing a distinct, neuro-specific biomarker (nsPAA) unique to schizophrenia.

To capture this target with clinical precision, we engineered a patented synthetic dimeric peptide that acts as biological bait within a sophisticated, semi-quantitative ELISA framework. Our commercial moat is further fortified by patent-pending platform optimizations designed to continuously expand our proprietary technology and secure a long-term global intellectual property runway.

A Standardized, Turnkey Laboratory Assay.

Seamlessly integrating our proprietary peptide dimer into standard global laboratory workflows.

Routine Collection

Standard venous blood draw at point-of-care. No specialized handling or proprietary collection devices required.

Standard Processing

Commercial-grade ELISA kit. Seamlessly integrates into existing global lab infrastructure without proprietary hardware.

Targeted Capture

Our patented synthetic peptide dimer selectively captures nsPAA, filtering out biological background noise.

Objective Readout

Delivers precise semi-quantitative data to reduce misdiagnosis, support early labelling and guide TRS interventions.

Our Team.

Alon Chen, Ph.D
Scientific Vision

President of Weizmann Institute of Science. Leading expert in the neurobiology of stress and its link to psychiatric disorders.

Sharon Manashirov, Dr.rer.nat
Head of Research and Business Development

Dr. Manashirov brings over 15 years of expertise in the neurobiology of mental disorders. As the former CEO of miCure Therapeutics, he excels at bridging the gap between sophisticated biological R&D and commercial asset strategy.

Hilik Levkovitch , M.D., Ph.D.
Senior Clinical Advisor

Prof Levkovitch Anchors our clinical validation roadmap. A premier psychiatric authority and active hospital director, he is the former President of the Israel Society for Biological Psychiatry.

Mila Schechtman, M.Sc.
Senior Scientist

Former head of laboratory activities and co-inventor of the schizophrenia immunoassay. Instrumental in technology transfer and continues in an advisory capacity.

Yechiel Goldman, Ph. D.
Advisor, Regulatory Affairs & Documentation

Dr. Goldman leverages comprehensive biotech and pharma regulatory experience to direct high-stakes clinical report architectures, ensuring seamless alignment with global health authority expectations.

Erika Ammirati, R.A.C., MT(ASCP)
Lead Regulatory Advisor

Over 45 years of IVD industry experience. Expert in navigating complex FDA approval processes and ensuring regulatory precision.